Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer’s Disease (CROSBI ID 303498)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Osmanović Barilar, Jelena ; Knezović, Ana ; Homolak, Jan ; Babić Perhoč, Ana ; Šalković-Petrišić, Melita Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer’s Disease // International journal of molecular sciences, 23 (2022), 1; 548, 16. doi: 10.3390/ijms23010548

Podaci o odgovornosti

Osmanović Barilar, Jelena ; Knezović, Ana ; Homolak, Jan ; Babić Perhoč, Ana ; Šalković-Petrišić, Melita

engleski

Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer’s Disease

The incretin system is an emerging new field that might provide valuable contributions to the research of both the pathophysiology and therapeutic strategies in the treatment of diabetes, obesity, and neurodegenerative disorders. This study aimed to explore the roles of central glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) on cell metabolism and energy in the brain, as well as on the levels of these incretins, insulin, and glucose via inhibition of the central incretin receptors following intracerebroventricular administration of the respective antagonists in healthy rats and a streptozotocin-induced rat model of sporadic Alzheimer’s disease (sAD). Chemical ablation of the central GIP receptor (GIPR) or GLP-1 receptor (GLP-1R) in healthy and diseased animals indicated a region-dependent role of incretins in brain cell energy and metabolism and central incretin-dependent modulation of peripheral hormone secretion, markedly after GIPR inhibition, as well as a dysregulation of the GLP- 1 system in experimental sAD.

glucagon-like peptide-1 ; gastric inhibitory polypeptide ; hippocampus ; hypothalamus ; Alzheimer’s disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

23 (1)

2022.

548

16

objavljeno

1422-0067

10.3390/ijms23010548

Trošak objave rada u otvorenom pristupu

Povezanost rada

Temeljne medicinske znanosti

Poveznice
Indeksiranost